Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

TrialNet centers begin Diamyd vaccine studies for recent-onset type 1 diabetes

March 12, 2009

WAY-207024 is a novel orally active antagonist of GnRH receptor

March 12, 2009

FDA approves Dara's IND to begin phase I studies in humans of DB-959 for type 2 diabetes

March 12, 2009

Novel LXRbeta ligands discovered by Roche

March 12, 2009

Tolerx initiates enrollment in phase III DEFEND trial of otelixizumab in Europe

March 11, 2009

Generex Biotechnology presents successful phase III data for Generex Oral-lyn

March 11, 2009

Novel androgen receptor agonists developed by Takeda

March 11, 2009

Merck & Co. presents novel pyridine carboxamide orexin receptor antagonists

March 10, 2009

Acrux completes enrollment in phase III Axiron trial in hypogonadal men

March 9, 2009

FDA to apply December 2008 guidance when reviewing Takeda's NDA for alogliptin

March 9, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...